Brunswick Exploration Acquires More Highly Prospective Lithium Targets in Greenland

Brunswick Exploration Acquires More Highly Prospective Lithium Targets in Greenland GlobeNewswire February 03, 2026 MONTREAL, Feb. 03, 2026 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW; OTCQB: BRWXF; Frankfurt: 1XQ) (“BRW” or the “Company“) is pleased to announce the staking of new high-priority lithium targets in Eastern Greenland, known as Clavering and Hudson Land. With […]

Harfang Outlines Winter Exploration Plans

Harfang Outlines Winter Exploration Plans GlobeNewswire February 03, 2026 MONTREAL, Feb. 03, 2026 (GLOBE NEWSWIRE) — Harfang Exploration Inc. (TSX-V: HAR) (“Harfang” or the “Company“) announces fully-funded winter exploration plans for its portfolio of wholly-owned projects located in Eeyou Istchee James Bay, Quebec, and in Ontario (see Figure 1). HIGHLIGHTS At Serpent, the Company will

Tilray Brands Ignites Championship Sunday: Nationwide Tap Room Events, Big Game Day Deals, and Fan Experiences Announced

Tilray Brands Ignites Championship Sunday: Nationwide Tap Room Events, Big Game Day Deals, and Fan Experiences Announced Gear up for game day, Sunday, February 8, 2026, with ultimate fan experiences, beer, wings, whiskey, and more at SweetWater Brewing Co., Montauk Brewing Co., Breckenridge Brewery, Blue Point Brewing Co., 10 Barrel Brewing Co., Hop Valley Brewing

PyroGenesis Confirms Additional Independent Verification of Its Fumed Silica Meeting Commercial Grade “150”

PyroGenesis Confirms Additional Independent Verification of Its Fumed Silica Meeting Commercial Grade “150” Fumed silica is now confirmed as being commercial grade 150 by multiple labs. GlobeNewswire February 03, 2026 MONTREAL, Feb. 03, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes

Abcourt Mines announces the Appointment of Dany Cenac Robert as Vice-President, Communications and Corporate Development

Abcourt Mines announces the Appointment of Dany Cenac Robert as Vice-President, Communications and Corporate Development GlobeNewswire February 03, 2026 ROUYN-NORANDA, Quebec, Feb. 03, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation“) (TSX Venture: ABI) (OTCQB: ABMBF) is very pleased to announce the appointment of Mr. Dany Cenac Robert to the position of

Expanded tax credits help offset fertility treatment costs for Canadians

Expanded tax credits help offset fertility treatment costs for Canadians H&R Block points to federal and provincial tax credits and reimbursements that can significantly reduce the cost of fertility treatment for Canadians GlobeNewswire February 03, 2026 CALGARY, Alberta, Feb. 03, 2026 (GLOBE NEWSWIRE) — It's estimated that between 8-15% of Canadian couples have difficulty conceiving

Vema Hydrogen Drills Pilot Wells in Quebec for World’s First Engineered Mineral Hydrogen Test Project

Vema Hydrogen Drills Pilot Wells in Quebec for World's First Engineered Mineral Hydrogen Test Project Pilot lays the groundwork for a new low-carbon energy engine capable of providing gigawatt-scale power to high-value industries GlobeNewswire February 03, 2026 Vema Hydrogen completes pilot wells to obtain core samples amidst Canadian snow SACRAMENTO, Calif., Feb. 03, 2026 (GLOBE

BellRing Brands Reports Results for the First Quarter of Fiscal Year 2026; Narrows Fiscal Year 2026 Outlook

BellRing Brands Reports Results for the First Quarter of Fiscal Year 2026; Narrows Fiscal Year 2026 Outlook GlobeNewswire February 03, 2026 ST. LOUIS, Feb. 03, 2026 (GLOBE NEWSWIRE) — BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global proactive wellness category, today reported results for the first fiscal quarter ended December 31,

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer GlobeNewswire February 03, 2026 Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 GlobeNewswire February 03, 2026 BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook:

Scroll to Top